Hamilton Thorne Provides Update on Going Private Transaction
Hamilton Thorne (TSX: HTL), a leading provider in the Assisted Reproductive Technologies (ART) field, has provided an update on its going private transaction with Cradle Acquisition Key points include:
- The transaction was approved by shareholders on September 17, 2024
- Final court approval was obtained on September 20, 2024
- Definitive agreements have been signed for the acquisition of Cook Medical's ART product portfolio
- All required regulatory approvals have been obtained
- The transaction and acquisition are expected to close on November 30, 2024
- Hamilton Thorne's shares will be delisted from the TSX upon closing
The company will also apply to cease being a reporting issuer in Canada.
- Shareholder approval obtained for the going private transaction
- Final court approval received for the transaction
- Definitive agreements signed for acquisition of Cook Medical's ART product portfolio
- All regulatory approvals obtained for both the transaction and acquisition
- Expected closing date set for November 30, 2024
- Delisting from TSX upon transaction closing
- Company to cease being a reporting issuer in Canada
Closing Expected to Occur Effective November 30, 2024
Beverly, Massachusetts and Toronto, Ontario--(Newsfile Corp. - October 17, 2024) - Hamilton Thorne Ltd (TSX: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies ("ART"), research, and the cell biology fields, today provided the following update to its going private transaction (the "Transaction") involving the Company and Cradle Acquisition LLC (the "Purchaser") pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the "Shares" and each, a "Share").
- As previously announced, the Transaction was overwhelmingly approved by its shareholders at a meeting held on September 17, 2024
- The Ontario Superior Court of Justice (Commercial List) provided final approval of the Transaction by order dated September 20, 2024
- The binding letter of intent that the Purchaser entered into to acquire (the "Acquisition") the ART product portfolio of Cook Medical ("Cook ART") with the intention to combine the Cook ART and Hamilton Thorne operations concurrently with the closing of the Transaction has been superseded by definitive agreements
- All required regulatory approvals relating to the Transaction and the Acquisition have been obtained by the Company, Cook and the Purchaser, as applicable, or such applicable waiting or review periods have lapsed without objection
- The Company expects the Transaction and the Acquisition will close effective November 30, 2024
In connection with the closing of the Transaction, the Shares will be delisted from the TSX and the Company will apply to cease to be a reporting issuer in each of the applicable jurisdictions in Canada.
For more information on the Transaction, please refer to the Company's Management Information Circular and the appended Arrangement Agreement, which are available on SEDAR+ (www.sedarplus.ca) under Hamilton Thorne's issuer profile.
About Hamilton Thorne
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and the cell biology fields. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, Tek-Event, Microptic, and Gynetics brands, through its growing sales force and distributors worldwide. Hamilton Thorne customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
For more information about Hamilton Thorne: https://www.hamiltonthorne.ltd/.
About Astorg
Astorg is a leading pan-European private equity firm with over €22 billion of assets under management and an extensive track record in global healthcare investments. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software, technology, business services and technology-based industrial companies. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan.
For more information about Astorg: https://www.astorg.com/. Follow Astorg on LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Such forward-looking information or statements ("FLS") are provided for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such FLS may be identified by words such as "proposed", "expects", "intends", "may", "will", and similar expressions. FLS contained or referred to in this press release includes, but is not limited to, statements regarding the proposed timing and various steps contemplated in respect of the Transaction or the Acquisition, the combination of the Cook ART and Hamilton Thorne operations, and the likelihood that the Transaction and the Acquisition will be consummated.
FLS is based on a number of factors and assumptions which have been used to develop such statements and information, but which may prove to be incorrect. Although the Company believes that the expectations reflected in such FLS are reasonable, undue reliance should not be placed on FLS because the Company can give no assurance that such expectations will prove to be correct. Factors that could cause actual results to differ materially from those described in such FLS include, without limitation, the following factors, many of which are beyond the Company's control and the effects of which can be difficult to predict: (a) the possibility that the Transaction will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, required shareholder, court and the Required Regulatory Approvals and other conditions of closing necessary to complete the Transaction or for other reasons; (b) the possibility of adverse reactions or changes in business relationships resulting from the announcement or completion of the Transaction or the Acquisition; (c) risks relating to the abilities of the parties to satisfy conditions precedent to the Transaction and the Acquisition; (d) credit, market, currency, operational, liquidity and funding risks generally and relating specifically to the Transaction and the Acquisition, including changes in economic conditions, interest rates or tax rates; (e) risks related to the Company resulting from the combination of the Company and the Cook ART operations in retaining existing customers and attracting new customers, retaining key personnel, executing on growth strategies, advancing its product line and protecting its intellectual property rights and proprietary information; (f) changes and trends in the Company's industry and the global economy; and (g) the identified risk factors included in the Company's public disclosure, including the annual information form dated March 27, 2024, which is available on SEDAR+ at www.sedarplus.ca. If any of these risks or uncertainties materialize, or if the assumptions underlying the FLS prove incorrect, actual results or future events might vary materially from those anticipated in the FLS. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in FLS, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such FLS. The FLS in this press release reflect the current expectations, assumptions, judgements and/or beliefs of the Company based on information currently available to the Company and are subject to change without notice.
Any FLS speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any FLS, whether as a result of new information, future events or results or otherwise, except as required under applicable securities laws. The FLS contained in this press release are expressly qualified by this cautionary statement. For more information on the Company, please review the Company's continuous disclosure filings that are available at www.sedarplus.ca.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The TSX accepts no responsibility for the adequacy or accuracy of this release.
For more information, investors and analysts please contact:
Kate Torchilin, David Wolf
Hamilton Thorne Ltd.
978-921-2050
IR@HamiltonThorne.ltd
Glen Akselrod
Bristol Investor Relations
905-326-1888
glen@bristolir.com
For more information, press please contact:
Hamilton Thorne
Aiden Woglom, Anne Hart
Prosek Partners
Pro-HamiltonThorne@prosek.com
Astorg
Samia Hadj
Shadj@Astorg.com
Prosek Partners
Pro-Astorg@prosek.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226896
FAQ
When is Hamilton Thorne's (HTLZF) going private transaction expected to close?
Has Hamilton Thorne (HTLZF) received shareholder approval for the going private transaction?
What will happen to Hamilton Thorne's (HTLZF) stock listing after the transaction closes?
Is Hamilton Thorne (HTLZF) acquiring Cook Medical's ART product portfolio?
